Literature DB >> 27132231

Inhibition of cerebral vascular inflammation by brain endothelium-targeted oligodeoxynucleotide complex.

Jing Hu1, Daniah Al-Waili1, Aishlin Hassan2, Guo-Chang Fan3, Mei Xin2, Jiukuan Hao4.   

Abstract

The present study generated a novel DNA complex to specifically target endothelial NF-κB to inhibit cerebral vascular inflammation. This DNA complex (GS24-NFκB) contains a DNA decoy which inhibits NF-κB activity, and a DNA aptamer (GS-24), a ligand of transferrin receptor (TfR), which allows for targeted delivery of the DNA decoy into cells. The results indicate that GS24-NFκB was successfully delivered into a murine brain-derived endothelial cell line, bEND5, and inhibited inflammatory responses induced by tumor necrosis factor α (TNF-α) or oxygen-glucose deprivation/re-oxygenation (OGD/R) via down-regulation of the nuclear NF-κB subunit, p65, as well as its downstream inflammatory cytokines, inter-cellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule (VCAM-1). The inhibitory effect of the GS24-NFκB was demonstrated by a significant reduction in TNF-α or OGD/R induced monocyte adhesion to the bEND5 cells after GS24-NFκB treatment. Intravenous (i.v.) injection of GS24-'NFκB (15mg/kg) was able to inhibit the levels of phoseph-p65 and VCAM-1 in brain endothelial cells in a mouse lipopolysaccharide (LPS)-induced inflammatory model in vivo. In conclusion, our approach using DNA nanotechnology for DNA decoy delivery could potentially be utilized for inhibition of inflammation in ischemic stroke and other neuro-inflammatory diseases affecting cerebral vasculature.
Copyright © 2016 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  NF-κB; aptamer; endothelial cells; inflammation; lipopolysaccharide; oxygen-glucose deprivation

Mesh:

Substances:

Year:  2016        PMID: 27132231      PMCID: PMC4905813          DOI: 10.1016/j.neuroscience.2016.04.033

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  75 in total

Review 1.  Series introduction: the transcription factor NF-kappaB and human disease.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia.

Authors:  N Laflamme; S Lacroix; S Rivest
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

3.  Structure of an IkappaBalpha/NF-kappaB complex.

Authors:  M D Jacobs; S C Harrison
Journal:  Cell       Date:  1998-12-11       Impact factor: 41.582

4.  In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction.

Authors:  R Morishita; T Sugimoto; M Aoki; I Kida; N Tomita; A Moriguchi; K Maeda; Y Sawa; Y Kaneda; J Higaki; T Ogihara
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

5.  Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin.

Authors:  Y Zhang; W M Pardridge
Journal:  Brain Res       Date:  2001-01-19       Impact factor: 3.252

6.  Transcription factor decoy oligodeoxynucleotides to nuclear factor-kappaB inhibit reverse passive Arthus reaction in rat.

Authors:  F D'Acquisto; A Ianaro; A Ialenti; P Maffia; M C Maiuri; R Carnuccio
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-11       Impact factor: 3.000

7.  T lymphocytes impair P-glycoprotein function during neuroinflammation.

Authors:  Gijs Kooij; Jack van Horssen; Elizabeth C M de Lange; Arie Reijerkerk; Susanne M A van der Pol; Bert van Het Hof; Joost Drexhage; Anke Vennegoor; Joep Killestein; George Scheffer; Ruud Oerlemans; Rik Scheper; Paul van der Valk; Christine D Dijkstra; Helga E de Vries
Journal:  J Autoimmun       Date:  2009-12-02       Impact factor: 7.094

8.  Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke.

Authors:  P J Lindsberg; O Carpén; A Paetau; M L Karjalainen-Lindsberg; M Kaste
Journal:  Circulation       Date:  1996-09-01       Impact factor: 29.690

9.  Protective effect of Ginkgolids (A+B) is associated with inhibition of NIK/IKK/IkappaB/NF-kappaB signaling pathway in a rat model of permanent focal cerebral ischemia.

Authors:  Xuan Wang; Zheng-Hong Qin; Hong Shi; Sean Isaac Savitz; Ai-Ping Qin; Yan Jiang; Hui-Ling Zhang
Journal:  Brain Res       Date:  2008-08-05       Impact factor: 3.252

Review 10.  Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells.

Authors:  Christine Dufès; Majed Al Robaian; Sukrut Somani
Journal:  Ther Deliv       Date:  2013-05
View more
  3 in total

Review 1.  Targeting vascular inflammation in ischemic stroke: Recent developments on novel immunomodulatory approaches.

Authors:  Shashank Shekhar; Mark W Cunningham; Mallikarjuna R Pabbidi; Shaoxun Wang; George W Booz; Fan Fan
Journal:  Eur J Pharmacol       Date:  2018-06-20       Impact factor: 4.432

2.  Beneficial Effects of Inflammatory Cytokine-Targeting Aptamers in an Animal Model of Chronic Prostatitis.

Authors:  Dong-Ru Ho; Pey-Jium Chang; Wei-Yu Lin; Yun-Ching Huang; Jian-Hui Lin; Kuo-Tsai Huang; Wai-Nga Chan; Chih-Shou Chen
Journal:  Int J Mol Sci       Date:  2020-05-31       Impact factor: 5.923

Review 3.  Targeting vascular inflammation through emerging methods and drug carriers.

Authors:  Jia Nong; Patrick M Glassman; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2022-03-07       Impact factor: 17.873

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.